Bronchiectasis: Chronic Airway Damage

Bronchiectasis is a structural lung condition in which the airways permanently widen and lose their ability to clear mucus effectively, creating a cycle of infection and inflammation that progressively damages bronchial walls. This page covers the definition, underlying mechanism, clinical scenarios in which bronchiectasis develops, and the boundaries that distinguish it from overlapping airway diseases. Understanding this condition matters because it is frequently underdiagnosed despite causing significant respiratory morbidity and driving repeated hospitalizations for pulmonary infection.

Definition and scope

Bronchiectasis refers to irreversible dilation of the bronchi — the medium and large conducting airways — resulting from destruction of the elastic and muscular components of the airway wall. The National Heart, Lung, and Blood Institute (NHLBI) classifies it as a chronic lung disease distinct from obstructive diseases like COPD and asthma, although it can coexist with both.

The condition is not a single disease entity. It is an anatomical endpoint shared by a range of underlying causes. Estimates from the American Thoracic Society (ATS) place the prevalence in the United States at approximately 200,000 diagnosed cases, though this is widely regarded as an undercount given that many patients are diagnosed late or attributed solely to recurrent pneumonia. Prevalence increases sharply after age 65, with women affected at higher rates than men across published registry data.

High-resolution computed tomography (HRCT) of the chest is the diagnostic standard recognized by the British Thoracic Society (BTS Guidelines on Bronchiectasis, 2019). Diagnosis requires demonstration of airway dilation — defined as an internal airway diameter greater than the diameter of the accompanying pulmonary artery — along with bronchial wall thickening and lack of airway tapering. Plain chest radiography is insufficiently sensitive for definitive diagnosis.

The broader landscape of pulmonary disease management, including how bronchiectasis fits within regulatory and clinical frameworks in the United States, is addressed in detail at the regulatory context for pulmonary resource.

How it works

The pathophysiology of bronchiectasis follows a self-reinforcing cycle described in pulmonary medicine as the "vicious cycle hypothesis," articulated extensively in peer-reviewed literature cited by the European Respiratory Society (ERS).

The cycle operates in four linked phases:

Initial injury or impaired clearance — An infection, inhalation injury, or genetic defect (such as primary ciliary dyskinesia or cystic fibrosis) prevents the normal mucociliary escalator from clearing pathogens and debris from the airway lumen.
Microbial colonization — Retained secretions allow bacteria — most commonly Pseudomonas aeruginosa and Haemophilus influenzae — to establish persistent colonization, triggering sustained neutrophilic inflammation.
Inflammatory airway wall destruction — Proteases released by neutrophils, particularly neutrophil elastase, degrade structural proteins including elastin and collagen in the bronchial wall, causing progressive dilation and loss of wall integrity.
Further impairment of clearance — Dilated, structurally compromised airways lose the mechanical properties needed to generate effective cough flow, worsening mucus retention and completing the cycle.

Three morphological subtypes are recognized on HRCT, each reflecting disease severity and distribution:

Cylindrical bronchiectasis — Uniform airway widening; the least severe form; associated with post-infectious or post-inflammatory causes.
Varicose bronchiectasis — Irregular airway widening with alternating constrictions; intermediate severity.
Cystic (saccular) bronchiectasis — Progressive ballooning of airway ends into cyst-like structures; associated with advanced disease, frequently seen in cystic fibrosis and severely immunocompromised patients.

Lung function testing, detailed at pulmonary function tests, typically demonstrates an obstructive or mixed obstructive-restrictive pattern, though a substantial subset of patients preserves near-normal spirometry even with radiologically severe disease.

Common scenarios

Bronchiectasis develops across a broad range of clinical contexts. The underlying etiology guides both prognosis and treatment strategy. The BTS 2019 guidelines recommend systematic etiologic workup in all newly diagnosed patients.

Post-infectious bronchiectasis is the single most common identifiable cause globally. Severe childhood pneumonia — particularly from measles, pertussis, or Mycobacterium tuberculosis — can permanently damage the developing airway. Tuberculosis remains a leading cause in high-prevalence populations and in patients born outside the United States.

Cystic fibrosis (CF) represents the best-characterized genetic cause, driven by mutations in the CFTR gene. All patients with CF develop bronchiectasis, typically beginning in the upper lobes.

Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder affecting ciliary function. The Genetic and Rare Diseases Information Center (GARD, NIH) estimates PCD affects approximately 1 in 10,000 individuals in the United States.

Immunodeficiency states — including common variable immunodeficiency (CVID) and hypogammaglobulinemia — lead to recurrent respiratory infections that progressively damage bronchial structure.

Aspiration and foreign body injury, allergic bronchopulmonary aspergillosis (ABPA), and connective tissue diseases (rheumatoid arthritis, Sjögren syndrome) account for additional identified cases. In approximately 30–50% of diagnosed adults, no specific cause is identified despite full evaluation, yielding a classification of idiopathic bronchiectasis.

Decision boundaries

Distinguishing bronchiectasis from overlapping airway diseases requires attention to specific radiological, physiological, and clinical features.

Bronchiectasis vs. COPD — Both produce chronic airflow obstruction and productive cough. COPD predominantly involves small airway disease and emphysematous destruction of alveolar tissue; bronchiectasis involves large and medium airway dilation visible on HRCT. The two conditions coexist in a clinically important subset of patients, particularly those with a long smoking history combined with a prior severe respiratory infection. The pulmonary function tests page covers spirometric and diffusion capacity patterns that help distinguish the contributions of each process.

Bronchiectasis vs. chronic bronchitis — Chronic bronchitis (a clinical diagnosis based on cough with sputum production for at least 3 months per year in 2 consecutive years, per the NHLBI definition) does not require structural airway dilation. Not all chronic bronchitis progresses to bronchiectasis, and bronchiectasis can exist without meeting the clinical criteria for chronic bronchitis.

Bronchiectasis vs. asthma — Asthma involves reversible airway narrowing driven by inflammation and bronchospasm; bronchiectasis involves irreversible structural dilation. ABPA, an allergic reaction to Aspergillus fumigatus fungal colonization, occupies a specific intersection: it causes central bronchiectasis and occurs almost exclusively in patients with pre-existing asthma or cystic fibrosis. Distinguishing ABPA-related bronchiectasis from non-ABPA forms changes antifungal and corticosteroid treatment decisions.

Severity stratification uses validated scoring tools. The Bronchiectasis Severity Index (BSI), published in the European Respiratory Journal (2014), stratifies patients into mild, moderate, and severe categories based on 9 weighted clinical variables, predicting hospitalization and mortality risk at 4-year follow-up.

For a broader orientation to pulmonary conditions covered across this resource, the pulmonaryauthority.com index provides a structured entry point.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)